Statement of Changes in Beneficial Ownership (4)
06 May 2015 - 6:58AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Stolz Brian M.
|
2. Issuer Name
and
Ticker or Trading Symbol
Valeant Pharmaceuticals International, Inc.
[
VRX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
_____ 10% Owner
__
X
__ Officer (give title below)
_____ Other (specify below)
EVP, Administration & CHCO
|
(Last)
(First)
(Middle)
2150 ST. ELZEAR BLVD. WEST
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
5/1/2015
|
(Street)
LAVAL, A8 H7L 4A8
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock, no par value
|
5/1/2015
|
|
M
|
|
3675
(2)
|
A
|
(1)
|
96060
|
D
|
|
Common Stock, no par value
|
5/1/2015
|
|
F
|
|
1921
(3)
|
D
|
$0
|
94139
|
D
|
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Restricted Share Units
|
(1)
|
5/1/2015
|
|
M
|
|
|
3675
(2)
|
(2)
|
(2)
|
Common Stock
|
3675
|
$0
|
0
|
D
|
|
Explanation of Responses:
|
(
1)
|
Each performance-based Restricted Share Unit ("PSU") represents a contingent right to receive between zero and three common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant"), subject to performance based vesting criteria. See note (2).
|
(
2)
|
This represents the number of units vested on the PSUs that were previously reported on the original Form 4. The initial grant was reported to vest based on total shareholder return ("TSR") between a price of $43.50 starting on December 7, 2011 and the average stock price for the 20 trading days starting on each measurement dates: 25% on September 7, 2014, 50% on December 7, 2014 and 25% on March 7, 2015. Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. These performance-based RSUs have now vested in full.
|
(
3)
|
This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of performance-based RSUs.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Stolz Brian M.
2150 ST. ELZEAR BLVD. WEST
LAVAL, A8 H7L 4A8
|
|
|
EVP, Administration & CHCO
|
|
Signatures
|
by: Nicholas Zanoni for Brian Stolz
|
|
5/5/2015
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Bausch Health Cos (New York Stock Exchange): 0 recent articles
More Valeant Pharmaceuticals International, Inc. News Articles